)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Genfit (GNFT) investor relations material
Genfit Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary22 Sep, 2025
Executive summary
Cash and cash equivalents reached €107.5 million as of June 30, 2025, excluding a €26.5 million milestone received in July 2025 for Iqirvo® pricing and reimbursement in three major European countries.
Revenues for 1H25 were €35.7 million, down from €61.2 million in 1H24, mainly from milestone and royalty payments related to Iqirvo®.
Net loss for 1H25 was €10.0 million, compared to a net profit of €30.3 million in 1H24, driven by higher R&D expenses and financial charges.
Discontinuation of the VS-01 program in ACLF is expected to reduce operating expenses and extend the cash runway beyond 2028.
Strong sales trajectory for Iqirvo® in PBC reported by Ipsen, with positive market dynamics following a competitor's US exit.
Financial highlights
Cash and cash equivalents increased to €107.5 million from €81.8 million at year-end 2024.
Revenues and other income totaled €35.7 million in 1H25, primarily from a €26.5 million milestone and €6.9 million in royalties.
Operating expenses rose to €35.6 million in 1H25, up from €30.0 million in 1H24, mainly due to increased R&D spending.
Financial loss of €10.2 million in 1H25, mainly due to debt issuance costs and royalty financing charges.
Net loss of €10.0 million in 1H25, compared to net profit of €30.3 million in 1H24.
Outlook and guidance
Cash runway projected to extend beyond 2028, supported by milestone revenues, royalty financing, and reduced expenses after VS-01 discontinuation.
Phase 1b data for GNS561 in CCA and safety/efficacy data for G1090N in ACLF expected by end of 2025.
Multiple ACLF pipeline assets advancing, with key clinical milestones anticipated through 2026 and 2027.
Market withdrawal of a key competitor in the US expected to benefit Iqirvo® sales.
ACLF pipeline prioritization post VS-01?
Iqirvo market share post OCALIVA US exit?
Royalty Financing impact on future profitability?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Genfit earnings date
Q3 2025 TU20 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Genfit S.A. is a biopharmaceutical company focused on discovering and developing innovative therapeutic and diagnostic solutions in the areas of liver-related diseases and metabolic disorders. The company specializes in creating proprietary drug candidates and biomarkers to address unmet medical needs, particularly in non-alcoholic steatohepatitis (NASH) and other chronic liver conditions. Genfit's portfolio includes both therapeutic and diagnostic assets aimed at improving patient outcomes through targeted treatment strategies and precision medicine. The company is headquartered in Loos, France, and its shares are listed on the Euronext Paris.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage